Home › Trial NCT04551053
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- Trial IDNCT04551053
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorIncyte Corporation
- Enrollment177
- Start date2021-05-26
- ConditionsMyelofibrosis · Primary Myelofibrosis · Post Essential Thrombocythemia Myelofibrosis · Post Polycythemia Vera Myelofibrosis
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.